Loading…
Loading…
This exchange-traded fund will allocate at least 80% of its net assets, including any capital acquired through borrowing for investment purposes, to financial instruments that are components of its underlying index or exhibit similar economic characteristics. The reference index is a market capitalization-weighted measure, adjusted for free float, and applies a 10/40 Constraint. Its objective is to gauge the equity market performance of Chinese enterprises within the healthcare sector. This fund does not maintain a diversified portfolio.
Is KURE's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Getting emerging market exposure is a viable option in the current market environment. That's especially so given the global de-dollarization and prospect of further rate cuts by the Federal Reserve.
Looking for a reason to consider adding exposure to the China healthcare sector to your portfolio? Now may actually be a very good time to do so.
When it comes to creating a well-diversified portfolio, healthcare stocks have traditionally offered a variety of benefits. As an innovative sector, healthcare companies offer the potential to build long-term portfolio growth.
With markets see-sawing up and down on a daily (or even minute-by-minute) basis on hints of global tariffs updates, there's an opportunity to time an investment to win short-term gains.
An escalating trade war with China elevates a number of risk factors, but also creates pockets of overlooked opportunity for those with the appetite. Advisors and investors looking for contrarian opportunities in 2025 need look no further than China's healthcare sector and the KraneShares MSCI China All Shares Healthcare 10/40 Index ETF (KURE).